Successful treatment of G-CSF-related aortitis with prednisolone during preoperative chemotherapy for breast cancer: a case report.

Aortitis Breast cancer Chemotherapy Granulocyte colony-stimulating factor Steroid

Journal

Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125

Informations de publication

Date de publication:
14 Jan 2021
Historique:
received: 21 11 2020
accepted: 05 01 2021
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 15 1 2021
Statut: epublish

Résumé

With the introduction of dose-dense therapy, the use of primary pegfilgrastim (PEG-G) has been increasing in breast cancer treatment. A rare side effect of PEG-G is aortitis. We describe a case of PEG-G-induced aortitis. The patient was a 43-year-old woman with stage IIA breast cancer. Due to the subtype of triple-negative breast cancer, preoperative dose-dense epirubicin-cyclophosphamide chemotherapy was started. PEG-G was administered on day 3 after the first cycle of epirubicin-cyclophosphamide chemotherapy. On day 11, she had a fever (39.4 °C) and an elevated C-reactive protein level (27.1 mg/dL). Emergency computed tomography revealed diffused wall thickening of the aortic arch without any other signs of infection. Despite administering antibiotics, her general condition and laboratory findings deteriorated until day 18. Based on these observations, she was diagnosed with PEG-G-induced aortitis. Antibiotics were discontinued, and she was treated with prednisolone thereafter. Subsequently, her clinical symptoms and laboratory findings improved around day 39. A second computed tomography scan revealed a decrease in the aortic arch wall thickening, and she was discharged on day 43. We successfully treated PEG-G-induced aortitis using prednisolone. Although this side effect is rare, cancer patients receiving PEG-G for chemotherapy should be monitored for aortic inflammation.

Sections du résumé

BACKGROUND BACKGROUND
With the introduction of dose-dense therapy, the use of primary pegfilgrastim (PEG-G) has been increasing in breast cancer treatment. A rare side effect of PEG-G is aortitis. We describe a case of PEG-G-induced aortitis.
CASE PRESENTATION METHODS
The patient was a 43-year-old woman with stage IIA breast cancer. Due to the subtype of triple-negative breast cancer, preoperative dose-dense epirubicin-cyclophosphamide chemotherapy was started. PEG-G was administered on day 3 after the first cycle of epirubicin-cyclophosphamide chemotherapy. On day 11, she had a fever (39.4 °C) and an elevated C-reactive protein level (27.1 mg/dL). Emergency computed tomography revealed diffused wall thickening of the aortic arch without any other signs of infection. Despite administering antibiotics, her general condition and laboratory findings deteriorated until day 18. Based on these observations, she was diagnosed with PEG-G-induced aortitis. Antibiotics were discontinued, and she was treated with prednisolone thereafter. Subsequently, her clinical symptoms and laboratory findings improved around day 39. A second computed tomography scan revealed a decrease in the aortic arch wall thickening, and she was discharged on day 43.
CONCLUSIONS CONCLUSIONS
We successfully treated PEG-G-induced aortitis using prednisolone. Although this side effect is rare, cancer patients receiving PEG-G for chemotherapy should be monitored for aortic inflammation.

Identifiants

pubmed: 33443626
doi: 10.1186/s40792-021-01111-z
pii: 10.1186/s40792-021-01111-z
pmc: PMC7807411
doi:

Types de publication

Journal Article

Langues

eng

Pagination

23

Références

Expert Opin Drug Saf. 2003 Jul;2(4):401-9
pubmed: 12904096
Mod Rheumatol. 2013 Nov;23(6):1231-6
pubmed: 22933310
Lupus. 2016 Oct;25(12):1381-4
pubmed: 27009623
Int J Clin Oncol. 2002 Feb;7(1):62-5
pubmed: 11942052
Nephrology (Carlton). 2009 Feb;14(1):33-41
pubmed: 19335842
J Rheumatol. 2006 Sep;33(9):1878-80
pubmed: 16832843
JCO Oncol Pract. 2021 Jan;17(1):57-58
pubmed: 32644903
Transfusion. 2011 Feb;51(2):319-27
pubmed: 20804529
Cytokine. 2019 Jul;119:47-51
pubmed: 30875590
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Acta Haematol. 2006;115(1-2):117-22
pubmed: 16424662
Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913
pubmed: 23076939
Rev Med Interne. 2004 Mar;25(3):225-9
pubmed: 14990294
Ann Pharmacother. 2002 Jan;36(1):130-47
pubmed: 11816242

Auteurs

Yoichi Koyama (Y)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. pioneer.1226.suck@gmail.com.

Kayo Adachi (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Mio Yagi (M)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Yoko Go (Y)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Kyoko Orimoto (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Saori Kawai (S)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Natsuki Uenaka (N)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Miki Okazaki (M)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Mariko Asaoka (M)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Saeko Teraoka (S)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Ai Ueda (A)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Kana Miyahara (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Takahiko Kawate (T)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Hiroshi Kaise (H)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Kimito Yamada (K)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Takashi Ishikawa (T)

Department of Breast Oncology and Surgery, Tokyo Medical University, 6-1-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.

Classifications MeSH